查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466040

移植HLA型检测市场：依产品与服务、技术、移植类型、应用、最终用户 - 2024-2030 年全球预测

HLA Typing for Transplant Market by Product & Service, Technology, Transplant Type, Application, End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年移植HLA型检测市场规模为9.9831亿美元，预计2030年将达18.3658亿美元，复合年增长率为9.09%。

人类白血球抗原 (HLA) 分型是移植医学中的重要过程，可辨识细胞表面上称为 HLA 抗原的特定蛋白质。移植的HLA型检测用于确认、匹配和监测器官、组织和干细胞移植的供体和受体的兼容性。这个过程可以降低移植物排斥的风险并改善患者的整体治疗效果，对于成功移植至关重要。此外，由于肾衰竭、肝硬化、心臟衰竭、糖尿病和血液疾病等慢性疾病的增加，对器官移植的需求不断增长。精准医学的进步将带来基于个体基因组成的个人化方法，以提高捐赠者和接受者之间的兼容性。然而，进行此类测试需要更多训练有素的专业人员，并且围绕器官移植的同意政策存在伦理问题，使得人类白血球抗原（HLA）过程的执行更加困难。此外，次世代定序(NGS)、基于 PCR 的技术和Sanger定序等HLA型检测方法的技术进步也有助于提高准确性并加快供体-受体匹配过程。政府透过促进器官捐赠和医疗基础设施投资的宣传宣传活动提供支持，进一步支持市场扩张。

主要市场统计
基准年[2023] 9.9831亿美元
预测年份 [2024] 1,086,390,000 美元
预测年份 [2030] 18.3658亿美元
复合年增长率（%） 9.09%

技术采用分子检测技术，具有高特异性和重现性

分子检测技术因其高解析度、特异性和重现性而越来越多的采用。基于序列的分型 (SBT) 技术涉及对 HLA 基因的外显子区域进行定序，以确定供体或患者样本中存在的等位基因。该方法提供了尽可能高的分辨率，并允许捐赠者和接受者的准确匹配。此外，聚合酵素链锁反应(PCR) 方法涉及扩增目标 HLA 基因区域，然后进行探针杂合反应或限制性片段长度多态性 (RFLP) 分析，以鑑定特定的等位基因。非分子检测技术包括透过血清学和细胞学方法HLA型检测。这些主要用于低解析度打字足够或由于成本或资源限製而无法使用分子方法时。血清学方法使用从先前分型的个体获得的抗血清来测试血清样本中是否存在特定的 HLA 抗原。细胞测定透过测量供体和受体免疫细胞在体外相互反应的能力来评估供体和受体免疫细胞的相容性。

产品和服务：优先考虑促进资料解释和实验室工作流程管理的软体和服务

提供准确、高效的移植相容性测试结果的仪器在HLA型检测过程中发挥关键作用。这包括定序仪、基于 PCR 的设备和其他测试设备。试剂和耗材是HLA型检测过程的重要组成部分，因为它们确保测试结果的再现性、敏感度、特异性和可靠性。其中包括 DNA 扩增试剂、DNA序列测定试剂（基于 NGS）、探针杂合反应测定试剂套件、微阵列/固相测定以及实验室使用的品管材料和标准品。软体和服务对于HLA型检测流程至关重要，因为它们有助于资料解释、结果报告和实验室工作流程管理。使用资料分析软体、资料库管理系统和能力验证品质保证程序。

移植类型：干细胞移植疗法越来越多地用于治疗白血病、淋巴瘤、骨髓瘤和免疫系统疾病。

器官移植以捐赠者的健康器官取代受损或无功能的器官。干细胞移植治疗方法多种血液相关疾病，包括白血病、淋巴瘤、骨髓瘤和免疫系统疾病。这涉及将健康的造血干细胞移植到患者体内以替换受损或故障的细胞。干细胞移植中的HLA型检测对于确保供体和受体细胞的相容性并降低移植物抗宿主疾病 (GVHD) 的风险至关重要。组织移植涉及将健康的捐赠者组织（例如角膜、骨髓、血管或皮肤）移植到受体体内，以恢復器官功能或改善患者的生活品质。

HLA型检测在应用器官移植诊断应用的应用

HLA型检测适用于器官移植、造血干细胞移植和输血医学的诊断应用，以确认捐赠者和受体之间的相容性。 HLA型检测有助于识别相容器官，从而降低移植物排斥的风险并改善患者预后。 HLA型检测广泛应用于群体遗传学、疾病相关研究、疫苗开发、药物基因体学研究及精准医学计画等研究应用。此外， HLA型检测提供了一种有效的工具来产生支持医学进步的可靠资料。

最终用户：寻求高通量能力和可扩展性的独立参考实验室的高普及率

医院和移植中心构成了移植HLA型检测分型的核心最终使用者部分。这些设施进行组织配对，以确定捐赠者和接受者之间的兼容性，确保器官和骨髓移植的成功。 HLA 为HLA型检测服务提供快速週转、高精度且经济高效的解决方案。独立参考实验室在商业性向医院和移植中心提供专门的诊断测试服务，例如HLA型检测。这些实验室因其高通量能力、扩充性和提高效率的技术进步而受到青睐。研究机构和学术机构利用次世代定序（NGS）、基于PCR的方法和HLA型检测的Sanger定序等先进技术进行移植生物学科学研究。该部门主要寻求创新技术、易于使用的平台和广泛的支援服务，以促进新调查方法的无缝实施。

区域洞察

由于技术进步和众多器官移植手术的可用性，用于移植的人类白血球抗原 (HLA) 分型市场正在全球显着增长。在美国和加拿大，由于器官移植需求的不断增长， HLA型检测的需求也不断增加。美国国立卫生研究院 (NIH) 资助了多项研究倡议来改进HLA型检测技术。此外，由于技术进步带来更准确的HLA型检测结果以及医生和患者对器官移植的认识不断提高，美洲的人类白血球抗原 (HLA) 分型市场预计将出现高速成长。在欧洲，由于人口老化导致需要器官移植的慢性疾病盛行率增加等因素，对HLA型检测服务的需求正在稳步增长。此外，有利的报销政策支持在欧洲接受移植手术的患者。沙乌地阿拉伯器官移植协会 (SSOT) 等组织致力于意识提升并加强国家之间的合作，例如波湾合作理事会(GCC) 器官移植计划。由于遗传病患病率高以及器官移植需求不断增长，中国、日本和印度对HLA型检测的需求不断增加。中国国家自然科学基金委员会正在资助新的HLA型检测技术的研究。此外，日本厚生劳动省也支持日本移植和细胞治疗协会 (JSTCT) 等计划。在印度，国家器官和组织移植组织 (NOTTO) 等政府措施透过提高公众对器官捐赠的认识来促进市场成长。

FPNV定位矩阵

FPNV定位矩阵对于评估移植HLA型检测市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可对可移植HLA型检测市场中供应商的现况进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，以获得市场竞争优势。

本报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.移植用HLA型检测市场的市场规模与预测是多少？

2.移植HLA型检测市场预测期间需要考虑投资的产品、细分市场、应用和领域有哪些？

3.移植HLA型检测市场的技术趋势与法规结构如何？

4.移植HLA型检测市场主要厂商的市场占有率是多少？

5. 进入移植HLA型检测市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 骨髓、器官和血液移植手术的发生率增加
      • 在个人化医疗中采用HLA型检测来减少移植物排斥
    • 抑制因素
      • 缺乏承保范围和保险不足
    • 机会
      • 移植诊断和HLA型检测方法领域的技术进步
      • 优先考虑免疫抑制治疗以补充HLA型检测
    • 任务
      • 对HLA型检测不准确的担忧
  • 市场区隔分析
    • 技术：采用分子检测技术，特异性高、重现性佳
    • 产品和服务：优先考虑促进资料解释和实验室工作流程管理的软体和服务
    • 移植类型：越来越多使用干细胞移植疗法来治疗白血病、淋巴瘤、骨髓瘤和免疫系统疾病
    • 应用： HLA型检测在器官移植的诊断应用的应用
    • 最终用户：独立参考实验室的高普及，可实现高通量能力和扩充性
  • 市场趋势分析
    • 先进的医疗保健发展和成熟市场供应商的存在将促进HLA型检测在美洲的扩展。
    • 移植HLA型检测市场在亚太地区正在迅速扩大，我们致力于引进先进技术来改善移植医疗基础设施。
    • 移植手术需求的不断增长以及政府对高品质HLA型检测商业化的支持为欧洲、中东和非洲地区创造了有利的市场条件
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析

第六章移植市场的HLA型检测（依产品与服务）

  • 装置
  • 试剂/耗材
  • 软体和服务

第七章 移植HLA型检测市场：依技术分类

  • 分子检测技术
  • 非分子检测技术

第八章 依移植类型分類的HLA型检测市场

  • 器官移植
  • 干细胞移植
  • 组织移植

第 9 章 移植HLA型检测市场：依应用分类

  • 诊断应用
  • 调查申请

第 10 章 移植HLA型检测市场：依最终使用者分类

  • 临床实验室/研究机构
  • 医院及移植中心
  • 独立参考实验室

第十一章 美洲HLA型检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太移植HLA型检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章 欧洲、中东和非洲移植HLA型检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • GenDx 推出 NGS-Turbo：利用 Oxford Nanopore Technologies 的定序设备彻底改变高解析度HLA型检测
    • Omixon 推出单重人类白血球抗原扩增套件NanoTYPE MONO 和 MONOall RUO，与 Oxford Nanopore 的 MinION 平台相容。
    • JURA Bio 宣布与 Replay 产品公司 Syena 合作，推进癌症 T 细胞受体 NK 疗法
    • Ossium Health 与 Be the Match 宣布合作，以提高骨髓移植的可近性和治疗效率
    • BriaCell接受NCI津贴开发癌症平台
    • Tempus 宣布与 TScan Therapeutics伴同性诊断合作
    • Metropolis Healthcare 推出下一代 HLA 器官移植检测
    • CD Genomics Longseq 部门宣布人类白血球抗原 (HLA) 分型服务
    • Garuda Therapeutics 获得 6,200 万美元 B 轮资金筹措，以推进现成的血液干细胞技术平台
    • FDA 已授予HLA型检测测试 De Novo 分类，用作转移性或不可切除的葡萄膜黑色素瘤 T 细胞受体治疗的诊断辅助。
    • Eurobioscientific 以 1.323 亿美元收购 GenDx
    • Be The Match BioTherapies 与 Atara Biotherapeutics 延长多年合作协议

第15章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-3D2FD205B873

[195 Pages Report] The HLA Typing for Transplant Market size was estimated at USD 998.31 million in 2023 and expected to reach USD 1,086.39 million in 2024, at a CAGR 9.09% to reach USD 1,836.58 million by 2030.

Human leukocyte antigen (HLA) typing is a vital process in medicine transplant that involves identifying specific proteins on the surface of cells, known as HLA antigens. The HLA typing for the transplant is used to identify, match, and monitor compatibility between donors and recipients for organ, tissue, or stem cell transplantation. This process is crucial to ensure a successful transplant by reducing the risk of graft rejection and improving overall patient outcomes. Moreover, the rising demand for organ transplants is due to an increase in chronic diseases such as kidney failure, liver cirrhosis, heart failure, diabetes mellitus, and hematological disorders. Precision medicine advancements can lead to personalized approaches based on individual genetic makeup for improved compatibility between donors and recipients. However, there is a need for more trained professionals performing these tests and ethical concerns surrounding organ transplantation consent policies, which restrict the growth of the Human leukocyte antigen (HLA) processes. Furthermore, technological advancements in HLA typing methods such as Next-Generation Sequencing (NGS), PCR-based techniques, and Sanger sequencing contribute to improved accuracy and a faster donor-recipient matching process. Government support through awareness campaigns promoting organ donation and investments in healthcare infrastructure further drive market expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 998.31 million
Estimated Year [2024] USD 1,086.39 million
Forecast Year [2030] USD 1,836.58 million
CAGR (%) 9.09%

Technology: Adoption of molecular assay technologies due to their high specificity and reproducibility

Molecular assay technologies are increasingly adopted due to their high resolution, specificity, and reproducibility. Sequence-based typing (SBT) techniques involve sequencing exon regions of HLA genes to determine the alleles present in a donor or patient sample. This method provides the highest resolution possible, allowing for precise matching between donors and recipients. In addition, Polymerase chain reaction (PCR) techniques rely on the amplification of target HLA gene regions followed by probe hybridization or restriction fragment length polymorphism (RFLP) analysis to identify specific alleles. Non-molecular assay technologies involve serological and cellular methods for HLA typing. They are primarily used when low-resolution typing is sufficient or where molecular methods may not be accessible due to cost or resource constraints. Serological techniques involve testing serum samples for the presence of specific HLA antigens using antisera obtained from previously typed individuals. Cellular assays assess the compatibility between donor and recipient immune cells by measuring their ability to respond to each other in-vitro.

Product & Service: Preference for software and services to facilitate data interpretation and managing laboratory workflow

Instruments play a crucial role in the HLA typing process as they provide accurate and efficient results for transplant compatibility testing. This includes sequencers, PCR-based instruments, and other laboratory equipment. Reagents and consumables are essential components of the HLA typing process as they ensure reproducibility, sensitivity, specificity, and reliability of test results. This constitutes DNA amplification reagents, DNA sequencing reagents (NGS-based), kits for probe hybridization assays, microarrays/solid-phase assays, and quality control materials & standards used in laboratories. Software and services are integral to the HLA typing process as they facilitate data interpretation, reporting of results, and laboratory workflow management. The software for data analysis, database management systems, and quality assurance programs for proficiency testing are used.

Transplant Type: Increasing use of stem cell transplantation therapy for leukemia, lymphoma, myeloma, and immune system diseases

Organ transplantation involves replacing a damaged or non-functional organ with a healthy one from a donor. HLA typing is essential in this process to minimize the risk of graft rejection due to immune system response, Stem cell transplantation is a therapy for various blood-related disorders such as leukemia, lymphoma, myeloma, and immune system diseases. It involves transplanting healthy hematopoietic stem cells into a patient to replace damaged or dysfunctional cells. HLA typing in stem cell transplantation is vital for ensuring the compatibility of donor and recipient cells, reducing the risk of graft-versus-host disease (GVHD). Tissue transplantation involves grafting healthy donor tissues such as corneas, bone marrow, blood vessels, and skin onto a recipient to restore the function of organs or improve the quality of patient's lives.

Application: Use of HLA typing in diagnostic applications for organ transplantation

HLA typing is preferred for diagnostic applications to ensure compatibility between donors and recipients for organ transplantation, hematopoietic stem cell transplantation, and transfusion medicine. It helps identify suitable matches to reduce the risk of graft rejection and improve patient outcomes. HLA typing is widely used in research applications for population genetics, disease association studies, vaccine development, pharmacogenomics research, and precision medicine initiatives. In addition, it provides efficient tools to generate robust data supporting advancements in medical science.

End-User: High penetration in independent reference laboratories for high-throughput capabilities and scalability

Hospitals and transplant centers form the core end-user segment for HLA typing for transplant purposes. These facilities perform tissue typing to determine compatibility between donors and recipients, ensuring successful organ or bone marrow transplants. HLA causes rapid turnaround time, high accuracy, and cost-effective solutions in HLA typing services. Independent reference laboratories provide specialized diagnostic testing services such as HLA typing to hospitals and transplant centers commercially. They are preferred due to high-throughput capabilities, scalability, and technological advancements that enhance efficiency. Research laboratories and academic institutes conduct scientific studies on transplantation biology using advanced techniques such as Next-Generation Sequencing (NGS), PCR-based methods, or Sanger sequencing for HLA typing. This segment primarily seeks innovative technologies, user-friendly platforms, and extensive support services to facilitate the seamless adoption of new methodologies.

Regional Insights

The Human leukocyte antigen (HLA) typing for transplant market is experiencing significant growth worldwide due to technological advancements and the availability of numerous organ transplant procedures. In the United States and Canada, demand for HLA typing is increasing due to growing organ transplantation needs. The National Institutes of Health (NIH) in the U.S. has funded numerous research initiatives to improve HLA typing techniques. Moreover, the Americas human leukocyte antigen (HLA) typing market is expected to grow at a higher rate due to increasing awareness about organ transplantation among both physicians and patients, along with technological advancements leading to more accurate HLA typing results. Europe has witnessed a steady increase in demand for HLA typing services owing to factors such as an aging population that increases the prevalence of chronic diseases requiring organ transplantation. Additionally, favorable reimbursement policies have supported patients undergoing transplant procedures in Europe. Organizations such as the Saudi Society for Organ Transplantation (SSOT) are working to increase awareness and collaborations between nations, such as the Gulf Cooperation Council (GCC) Organ Transplant Program. China, Japan, and India are witnessing an increased demand for HLA typing due to a high prevalence of genetic disorders and growing organ transplantation needs. China's National Natural Science Foundation has funded research on novel HLA typing techniques. Moreover, Japan's Ministry of Health, Labor, and Welfare supports projects such as the Japan Society for Transplantation and Cellular Therapy (JSTCT). In India, government initiatives, such as the 'National Organ and Tissue Transplant Organization (NOTTO) contribute to market growth by increasing public awareness about organ donation.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the HLA Typing for Transplant Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the HLA Typing for Transplant Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the HLA Typing for Transplant Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., BAG Diagnostics GmbH, Becton, Dickinson, and Company, BGI Genomics Co.,Ltd., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, CapitalBio Technology Co., Ltd., CareDx, Inc., CeGaT GmbH, Chugai Pharmaceutical Co., Ltd., Creative Biolabs, Inc., DiaSorin S.p.A., Eurofins Scientific SE, F. Hoffman-La Roche AG, Fujirebio, Inc. by H.U. Group Holdings, Inc., Garuda Therapeutics, GenDx by Eurobio Scientific Group, HEALIOS K.K., Hologic, Inc., Illumina, Inc., Immatics N.V., Immucor, Inc. by Werfen, S.A., ImmunOs Therapeutics AG, Invectys Inc., Laboratory Corporation of America Holdings, Lonza Group Ltd., Merck KGaA, NeoGenomics Laboratories, Inc., OraSure Technologies, Inc., Oxford Nanopore Technologies PLC, Pure MHC, LLC, Pure Protein, LLC, QIAGEN N.V., STEMCELL Technologies Inc., T-Cure Bioscience Inc., Takara Bio Inc., TBG Diagnostics Ltd., TCR2 Therapeutics by Adaptimmune Therapeutics PLC, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the HLA Typing for Transplant Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product & Service
    • Instruments
    • Reagents & Consumables
    • Software & Services
  • Technology
    • Molecular Assay Technologies
      • PCR-Based Molecular Assays
        • Real-Time PCR
        • Sequence-Specific Oligonucleotide-PCR
        • Sequence-Specific Primer-PCR
      • Sequencing-Based Molecular Assays
        • Next-Generation Sequencing
        • Sanger Sequencing
    • Non-Molecular Assay Technologies
  • Transplant Type
    • Organ Transplantation
    • Stem Cell Transplantation
    • Tissue Transplantation
  • Application
    • Diagnostic Applications
      • Antibody Screening
      • Chimerism Monitoring
    • Research Applications
  • End-User
    • Clinical Laboratories & Research Institution
    • Hospitals & Transplant Centers
    • Independent Reference Laboratories
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the HLA Typing for Transplant Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the HLA Typing for Transplant Market?

3. What are the technology trends and regulatory frameworks in the HLA Typing for Transplant Market?

4. What is the market share of the leading vendors in the HLA Typing for Transplant Market?

5. Which modes and strategic moves are suitable for entering the HLA Typing for Transplant Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of bone marrow, organ, and blood transplant processes
      • 5.1.1.2. Adoption of HLA typing in personalized medicine for reduced graft rejections
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of reimbursement and inadequate insurance policies
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in the field of transplant diagnostics and HLA-typing methods
      • 5.1.3.2. Preference for immunosuppressive therapies to complement HLA typing
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns regarding the inaccuracy of HLA typing
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Adoption of molecular assay technologies due to their high specificity and reproducibility
    • 5.2.2. Product & Service: Preference for software and services to facilitate data interpretation and managing laboratory workflow
    • 5.2.3. Transplant Type: Increasing use of stem cell transplantation therapy for leukemia, lymphoma, myeloma, and immune system diseases
    • 5.2.4. Application: Use of HLA typing in diagnostic applications for organ transplantation
    • 5.2.5. End-User: High penetration in independent reference laboratories for high-throughput capabilities and scalability
  • 5.3. Market Trend Analysis
    • 5.3.1. Advanced Healthcare R&D and presence of established market vendors facilitate the expansion of HLA typing in Americas
    • 5.3.2. Dynamically expanding HLA typing for transplant market in the APAC, with emphasis on advanced technology adoption for offering improved healthcare infrastructure for transplantation
    • 5.3.3. Rising need for transplant procedures and government support for commercializing quality HLA typing to create a favorable market landscape in EMEA
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. HLA Typing for Transplant Market, by Product & Service

  • 6.1. Introduction
  • 6.2. Instruments
  • 6.3. Reagents & Consumables
  • 6.4. Software & Services

7. HLA Typing for Transplant Market, by Technology

  • 7.1. Introduction
  • 7.2. Molecular Assay Technologies
  • 7.3. Non-Molecular Assay Technologies

8. HLA Typing for Transplant Market, by Transplant Type

  • 8.1. Introduction
  • 8.2. Organ Transplantation
  • 8.3. Stem Cell Transplantation
  • 8.4. Tissue Transplantation

9. HLA Typing for Transplant Market, by Application

  • 9.1. Introduction
  • 9.2. Diagnostic Applications
  • 9.3. Research Applications

10. HLA Typing for Transplant Market, by End-User

  • 10.1. Introduction
  • 10.2. Clinical Laboratories & Research Institution
  • 10.3. Hospitals & Transplant Centers
  • 10.4. Independent Reference Laboratories

11. Americas HLA Typing for Transplant Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific HLA Typing for Transplant Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa HLA Typing for Transplant Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. GenDx launches NGS-Turbo: revolutionizing high-resolution HLA typing with Oxford Nanopore Technologies sequencing devices
    • 14.3.2. Omixon Launches NanoTYPE MONO and MONOall RUO, a Singleplex Human Leukocyte Antigen Amplification kit compatible with Oxford Nanopore's MinION Platform
    • 14.3.3. JURA Bio Announces Partnership With Replay Product Company Syena to Advance T Cell Receptor NK Therapies in Cancer
    • 14.3.4. Ossium Health and Be The Match Unveil Partnership to Increase Bone Marrow Transplant Accessibility and Treatment Efficiency
    • 14.3.5. BriaCell receives NCI grant for cancer platform development
    • 14.3.6. Tempus Announces Companion Diagnostic Collaboration with TScan Therapeutics
    • 14.3.7. Metropolis Healthcare unveils NextGen HLA test for organ transplantation
    • 14.3.8. CD Genomics Longseq Division Unveils Human Leukocyte Antigen (HLA) Typing Service
    • 14.3.9. Garuda Therapeutics Secures USD 62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
    • 14.3.10. FDA Grants De Novo Classification to HLA Typing Test for Use as a Companion Diagnostic with a T Cell Receptor Therapy for Metastatic or Unresectable Uveal Melanoma
    • 14.3.11. Eurobio Scientific acquires GenDx for USD 132.3 million
    • 14.3.12. Be The Match BioTherapies, Atara Biotherapeutics Ink Multi-Year Partnership Extension

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. HLA TYPING FOR TRANSPLANT MARKET RESEARCH PROCESS
  • FIGURE 2. HLA TYPING FOR TRANSPLANT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. HLA TYPING FOR TRANSPLANT MARKET DYNAMICS
  • FIGURE 7. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. HLA TYPING FOR TRANSPLANT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. HLA TYPING FOR TRANSPLANT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HLA TYPING FOR TRANSPLANT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCE-SPECIFIC PRIMER-PCR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCE-SPECIFIC PRIMER-PCR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ORGAN TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ORGAN TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TISSUE TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TISSUE TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ANTIBODY SCREENING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ANTIBODY SCREENING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY CHIMERISM MONITORING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY CHIMERISM MONITORING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY CLINICAL LABORATORIES & RESEARCH INSTITUTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY CLINICAL LABORATORIES & RESEARCH INSTITUTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 67. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INDEPENDENT REFERENCE LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 68. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INDEPENDENT REFERENCE LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 79. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 82. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 83. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 84. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 85. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 86. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 87. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 88. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 89. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 90. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 91. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 92. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 93. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 94. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 95. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 96. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 97. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 98. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 99. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 100. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 101. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 102. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 103. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 104. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 105. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 106. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 107. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 108. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 109. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 110. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 111. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 112. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 113. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 114. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 115. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 116. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 117. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 120. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 121. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 122. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 123. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 124. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 125. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 126. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 127. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 128. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 129. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 130. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 131. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 132. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 133. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 134. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 135. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 138. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 139. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 140. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 141. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 142. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 143. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 144. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 145. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 146. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 147. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 148. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 149. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 150. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 151. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 152. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 153. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 156. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 157. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 158. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 159. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 160. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 161. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 162. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 163. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 164. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 165. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 166. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 167. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 168. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 169. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 170. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 171. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 174. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 175. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 176. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 177. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 178. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 179. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 180. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 201. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 202. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 203. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 204. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 205. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 206. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 207. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 208. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 209. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 210. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 211. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 214. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 215. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 216. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 217. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 218. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 219. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 220. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 221. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 222. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 223. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 224. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 225. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 226. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 227. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 228. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 229. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 232. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 233. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 234. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 235. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 236. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 237. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 238. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 239. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 240. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 241. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 242. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 243. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 244. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 245. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 246. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 247. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 250. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 251. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 252. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 253. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 254. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 255. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 256. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 257. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 258. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 259. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 260. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 261. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 262. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 263. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 264. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 265. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 268. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 269. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 270. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 271. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 272. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 273. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 274. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 275. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 276. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 277. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 278. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 279. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 280. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 281. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 282. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 283. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 284. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 285. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 286. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 287. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
  • TABLE 288. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
  • TABLE 289. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 290. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 291. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
  • TABLE 292. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
  • TABLE 293. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 294. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 295. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
  • TABLE 296. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
  • TABLE 297. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 298. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 299. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
  • TABLE 300. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
  • TABLE 301. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
  • TABLE 302. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
  • TABLE 303. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 304. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD